NVS novartis.com: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Novartis AG is systematically implementing "green chemistry" and renewable energy into its production. The EV/EBITDA ratio trajectory demonstrates local dynamics, with the metric fixed at 15.22. The success of its transformation into an innovator is based on FDA approvals and patent protection, while a strong talent pool is supported by cutting-edge laboratories and a developed culture of mentorship.

Novartis Corporation - NVS Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/12/2026)

novartis.com - analytical breakdowns and key metrics (NVS)

- market price and analyst price targets:

Price Chart Novartis Inc.|NVS - Average Forecast Price

- company stock capitalization data:

Market Value Novartis Pharma|NVS - Total Company Value

- book value of equity indicators:

Book Value per Share Novartis|NVS - Accounting Capitalization|Market Capitalization to Book Value Ratio novartis.com|NVS - Company Total Asset Base

- business debt structure and liquidity details:

- financial results and valuation multiples details:

NVS - Company Net Income|Projected Future Earnings Novartis AG|NVS - P/E Multiple|Future Price to Earnings Novartis AG|NVS - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Novartis Pharma|NVS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Novartis|NVS - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months novartis.com|NVS - Expected net earnings per share growth this year|Expected earnings per share growth for next year Novartis AG

Basic company analysis:NVS (Novartis Inc.)

EV/EBITDA serves as a fundamental benchmark for determining the fair value of assets while accounting for debt load and tax obligations. This metric compares the total enterprise value of a business with its operating profit before depreciation and amortization, eliminating the influence of capital structure. By analyzing the EV/EBITDA multiple, an investor assesses the risk of overpaying for an asset. This is critical for Novartis AG (NVS), as the ultra-high margins of gene therapy must justify the market value of this behemoth.

Competitor analysis for Novartis AG